Exome Asset Management LLC reduced its position in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 30.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,300 shares of the company’s stock after selling 2,700 shares during the quarter. Exome Asset Management LLC’s holdings in Penumbra were worth $2,069,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC lifted its holdings in shares of Penumbra by 4,100.0% in the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after buying an additional 82 shares during the period. CIBC Private Wealth Group LLC increased its stake in shares of Penumbra by 2,700.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock valued at $26,000 after buying an additional 81 shares during the period. Motiv8 Investments LLC bought a new stake in shares of Penumbra in the fourth quarter valued at about $27,000. Morse Asset Management Inc bought a new stake in shares of Penumbra in the fourth quarter valued at about $39,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after acquiring an additional 38 shares in the last quarter. 88.88% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada restated a “sector perform” rating and issued a $374.00 price target on shares of Penumbra in a report on Thursday, June 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Citigroup dropped their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Finally, Zacks Research lowered shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Three research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $360.33.
Penumbra Price Performance
Shares of PEN stock opened at $319.46 on Tuesday. The stock’s 50-day moving average is $319.32 and its 200 day moving average is $330.05. Penumbra, Inc. has a 1-year low of $221.26 and a 1-year high of $362.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The company has a market cap of $12.56 billion, a P/E ratio of 73.61, a PEG ratio of 1.98 and a beta of 0.70.
Penumbra (NYSE:PEN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The firm had revenue of $374.76 million during the quarter, compared to the consensus estimate of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The firm’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.83 earnings per share. Research analysts predict that Penumbra, Inc. will post 5.02 earnings per share for the current fiscal year.
About Penumbra
Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.
At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.
Featured Stories
- Five stocks we like better than Penumbra
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
